BACKGROUND: The role of p53 in modulating apoptosis has suggested that it may affect efficacy of anticancer agents. We prospectively evaluated p53 alterations in 73 patients with locally advanced breast cancer (IIIB) submitted to neoadjuvant chemotherapy. PATIENTS AND METHODS: Patients received three cycles of paclitaxel (175 mg/m2) and doxorubicin (60 mg/m2) every 21 days. Tumor sections were analyzed before treatment for altered patterns of p53 expression using immunohistochemistry and DNA sequencing. RESULTS: An overall response rate of 83.5% was obtained, including 15.1% complete pathological responses. The regimen was well tolerated with 17.7% grade 2/3 nausea and 12.8% grade 3/4 leukopenia. There was a statistically significant correlation between response and expression of p53. Of the 25 patients who obtained a complete clinical response, two were classified as positive (P = 0.004, chi-square). Of 11 patients who obtained a complete pathological remission, one was positive (P = 0.099, chi-square). Discussion The combination is highly effective in locally advanced breast cancer. A negative expression of p53 indicates a higher chance of responding to this regimen. The p53 status may be used as a biological marker to identify those patients who would benefit from more aggressive treatments.
BACKGROUND: The role of p53 in modulating apoptosis has suggested that it may affect efficacy of anticancer agents. We prospectively evaluated p53 alterations in 73 patients with locally advanced breast cancer (IIIB) submitted to neoadjuvant chemotherapy. PATIENTS AND METHODS: Patients received three cycles of paclitaxel (175 mg/m2) and doxorubicin (60 mg/m2) every 21 days. Tumor sections were analyzed before treatment for altered patterns of p53 expression using immunohistochemistry and DNA sequencing. RESULTS: An overall response rate of 83.5% was obtained, including 15.1% complete pathological responses. The regimen was well tolerated with 17.7% grade 2/3 nausea and 12.8% grade 3/4 leukopenia. There was a statistically significant correlation between response and expression of p53. Of the 25 patients who obtained a complete clinical response, two were classified as positive (P = 0.004, chi-square). Of 11 patients who obtained a complete pathological remission, one was positive (P = 0.099, chi-square). Discussion The combination is highly effective in locally advanced breast cancer. A negative expression of p53 indicates a higher chance of responding to this regimen. The p53 status may be used as a biological marker to identify those patients who would benefit from more aggressive treatments.
Authors: Laura C Funk; Jun Wan; Sean D Ryan; Charanjeet Kaur; Ruth Sullivan; Avtar Roopra; Beth A Weaver Journal: Mol Cancer Res Date: 2020-09-18 Impact factor: 6.333
Authors: Adma Poliana Cecilio; Erika Tomie Takakura; Jaqueline Janaina Jumes; Jeane Wilhelm Dos Santos; Ana Cristina Herrera; Vanessa Jacob Victorino; Carolina Panis Journal: Breast Cancer (Dove Med Press) Date: 2015-01-29
Authors: Tomás Pascual; Mafalda Oliveira; Patricia Villagrasa; Vanesa Ortega; Laia Paré; Begoña Bermejo; Serafín Morales; Kepa Amillano; Rafael López; Patricia Galván; Jordi Canes; Fernando Salvador; Paolo Nuciforo; Isabel T Rubio; Antonio Llombart-Cussac; Serena Di Cosimo; José Baselga; Nadia Harbeck; Aleix Prat; Javier Cortés Journal: NPJ Breast Cancer Date: 2021-11-25
Authors: Brian M Nolen; Jeffrey R Marks; Shlomo Ta'san; Alex Rand; The Minh Luong; Yun Wang; Kimberly Blackwell; Anna E Lokshin Journal: Breast Cancer Res Date: 2008-05-12 Impact factor: 6.466